StreetInsider.com News Articles

Form 6-K Alvotech For: Oct 14

Wed, 14 Oct 2026 10:05:00 -0400

si-local-file:///var/storage/secattach/20261014/27185427.html

Alvotech files first known biosimilar application for Eylea 8 mg

Wed, 14 Oct 2026 06:04:56 -0400

Alvotech (NASDAQ: ALVO) and Advanz Pharma announced the submission of a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg (aflibercept 114.3 mg/mL), which is marketed as Eylea HD in the United States. According to the companies, based on publicly available information, this is the first regulatory submission worldwide for a proposed biosimilar to the 8 mg formulation.

The application was submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli, Alvotech's already-approved biosimilar to Eylea 2 mg. Mynzepli received European Commission approval in August 2025.

Eylea 8 mg allows treatment intervals

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Wed, 14 Oct 2026 04:30:00 -0400

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)

High-dose aflibercept offers the potential to reduce treatment frequency for patients with retinal diseases

REYKJAVIK, Iceland and LONDON, UK (October 14, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced the submission of a European regulatory application for AVT29, a

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Wed, 14 Oct 2026 04:30:00 -0400

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)

High-dose aflibercept offers the potential to reduce treatment frequency for patients with retinal diseases

Form 6-K Alvotech For: Oct 06

Wed, 07 Oct 2026 10:16:00 -0400

si-local-file:///var/storage/secattach/20261007/27159486.html

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Tue, 06 Oct 2026 16:30:00 -0400

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York

Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support growth in demand

REYKJAVIK, Iceland, and SEOUL, South Korea (October 6, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract development and manufacturing (CDMO) organization, today announced a long-term strategic manufacturing partnership.

Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse facility in New

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Tue, 06 Oct 2026 16:30:00 -0400

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York

Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support growth in demand

Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse facility in New

Alvotech stock surges after FDA manufacturing approval

Mon, 05 Oct 2026 11:06:05 -0400

Investing.com -- Alvotech SA (NASDAQ:ALVO) shares jumped 13.5% Monday after the U.S. Food and Drug Administration approved a supplement to the Biologics License Application for AVT02, enabling the company to manufacture the drug substance in a second production suite at its Reykjavik facility.

The approval allows Alvotech to produce AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI, in either of two drug substance suites at the Reykjavik site. The addition of the second suite, DSM2, effectively doubles the drug substance manufacturing capacity available to support U.S. supply and provides greater flexibility for commercial operations.

The approval follows the FDA's

Alvotech stock surges after FDA manufacturing approval

Mon, 05 Oct 2026 11:06:05 -0400

The approval follows the FDA's

Form 6-K Alvotech For: Oct 05

Mon, 05 Oct 2026 07:57:00 -0400

si-local-file:///var/storage/secattach/20261005/27145783.html

FDA approves second manufacturing suite for Alvotech's Simlandi biosimilar

Mon, 05 Oct 2026 04:00:15 -0400

The U.S. Food and Drug Administration has approved a supplement to the Biologics License Application for AVT02 (adalimumab-ryvk), marketed in the U.S. as Simlandi®, allowing Alvotech (NASDAQ: ALVO) to manufacture the drug substance for U.S. commercial supply in a second production suite at its Reykjavik, Iceland facility.

The newly approved suite, designated DSM2, supports the complete drug substance manufacturing process, including cell culture and purification. The addition of DSM2 means Alvotech can now produce AVT02 drug substance for U.S. supply in either DSM1 or DSM2, doubling the manufacturing capacity available for that market. DSM2 was already approved for commercial drug substance

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

Mon, 05 Oct 2026 04:00:00 -0400

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites

Further confirms resolution of FDA inspection-related matters at the Reykjavik site

REYKJAVIK, Iceland (October 5, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Biologics License Application (BLA) for AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI®, enabling drug substance for the product to be manufactured in a

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

Mon, 05 Oct 2026 04:00:00 -0400

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites

Further confirms resolution of FDA inspection-related matters at the Reykjavik site

Barclays Upgrades Alvotech SA (ALVO) to Overweight

Wed, 16 Sep 2026 01:24:56 -0400

Barclays analyst Glen Santangelo upgraded Alvotech SA (NASDAQ: ALVO) from Underweight to Overweight with a price target of $8.00 (from $4.00).

The analyst comments: “The performance in the balance of the year largely comes down to the expected Dec 4th (or sooner) decision by the FDA – we see 2x potential upside vs downside: The company’s extensive efforts in response to the CRLs issued by the FDA enabled the company to resubmit BLAs in June for the proposed biosimilars to Simponi (AVT05), Simponi Aria, Eylea (AVT06) and Prolia/Xgeva (AVT03). The FDA has acknowledged these re-submissions as complete responses to the prior

Barclays Upgrades Alvotech SA (ALVO) to Overweight

Wed, 16 Sep 2026 01:24:56 -0400

Barclays analyst Glen Santangelo upgraded Alvotech SA (NASDAQ: ALVO) from Underweight to Overweight with a price target of $8.00 (from $4.00).

BofA starts bullish Alvotech coverage on biosimilar launch cycle

Mon, 24 Aug 2026 06:14:19 -0400

Investing.com -- BofA Securities initiated coverage of Alvotech S.A. with a “buy” rating and a $7 price objective, versus the stock’s $4.43 price as of Monday, after the FDA’s closure of its inspection of the company’s Reykjavik manufacturing facility removed a key regulatory overhang and as the biosimilar developer enters what BofA called its most meaningful launch cycle since inception.

Shares of the company were up 2.7% in pre-open trade.

BofA’s price objective is based on a discounted cash flow analysis assuming a 10% discount rate and a 1% terminal growth rate.

The brokerage’s model projects 2026 earnings

BofA Securities Starts Alvotech SA (ALVO) at Buy

Mon, 24 Aug 2026 05:16:47 -0400

BofA Securities analyst Jason Gerberry initiates coverage on Alvotech SA (NASDAQ: ALVO) with a Buy rating and a price target of $7.00.

The analyst comments "We initiate coverage of Alvotech with a Buy rating and $7 PO. We see an attractive risk/reward as Alvotech’s multi-year investment in an integrated biosimilar development and manufacturing platform begins to translate into a higher-quality commercial growth story. While recent investor sentiment has been weighed down by regulatory uncertainty surrounding the Reykjavik manufacturing facility, the FDA’s closure of the inspection removes a key overhang and clears the path toward new approvals. Having achieved its first full

BofA Securities Starts Alvotech SA (ALVO) at Buy

Mon, 24 Aug 2026 05:16:47 -0400

BofA Securities analyst Jason Gerberry initiates coverage on Alvotech SA (NASDAQ: ALVO) with a Buy rating and a price target of $7.00.

Form 6-K Alvotech For: Aug 21

Fri, 21 Aug 2026 10:37:00 -0400

si-local-file:///var/storage/secattach/20260821/26959606.html

Form 6-K Alvotech For: Aug 21

Fri, 21 Aug 2026 10:37:00 -0400

si-local-file:///var/storage/secattach/20260821/26959606.html

Form 6-K Alvotech For: Jun 30

Wed, 19 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260819/26950584.html

Form 6-K Alvotech For: Jun 30

Wed, 19 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260819/26950584.html

Evercore ISI Starts Alvotech SA (ALVO) at Outperform

Fri, 14 Aug 2026 07:14:31 -0400

Evercore ISI analyst Umer Raffat initiates coverage on Alvotech SA (NASDAQ: ALVO) with a Outperform rating.

The analyst comments "We are expanding our spec pharma coverage universe and with a name which has all the hallmarks: super high leverage, FDA inspection issues, and a path to delevering if biosimilar launches go right. We believe that Alvotech’s recent FDA inspection classification of VAI has majorly derisked the BSUFA dates in 4Q. However, just because ALVO may get approvals on meaningful commercial opportunities like Simponi and Eylea HD etc doesn’t mean they can launch immediately: IP questions will remain."

For an analyst ratings summary

Evercore ISI Starts Alvotech SA (ALVO) at Outperform

Fri, 14 Aug 2026 07:14:31 -0400

Evercore ISI analyst Umer Raffat initiates coverage on Alvotech SA (NASDAQ: ALVO) with a Outperform rating.

For an analyst ratings summary

Form 6-K Alvotech For: Jul 29

Wed, 29 Jul 2026 11:00:00 -0400

si-local-file:///var/storage/secattach/20260729/26832729.html